Efficacy and safety of mirikizumab in psoriasis: results from a 52‐week, double‐blind, placebo‐controlled, randomized withdrawal, phase III trial (OASIS‐1)

BACKGROUND: Interleukin‐23 inhibitors are effective and safe for treating moderate‐to‐severe plaque psoriasis. OBJECTIVES: To evaluate the efficacy and safety of mirikizumab in adult patients with moderate‐to‐severe plaque psoriasis through 52 weeks in a phase III randomized controlled trial. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Kimball, Alexa B., Augustin, Matthias, Okubo, Yukari, Witte, Michael M., Capriles, Claudia Rodriguez, Sontag, Angelina, Arora, Vipin, Osuntokun, Olawale, Strober, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087045/
https://www.ncbi.nlm.nih.gov/pubmed/35791755
http://dx.doi.org/10.1111/bjd.21743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087045/
https://www.ncbi.nlm.nih.gov/pubmed/35791755
http://dx.doi.org/10.1111/bjd.21743

Ejemplares similares